MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB) today
announced that data relating to its proprietary PC-DAC(TM):Exendin-4 Albumin
Conjugate for the treatment of Type 2 diabetes will be presented at the 67th
Scientific Sessions of the American Diabetes Association (ADA) to be held
June 22-26, 2007 in Chicago, IL. The ADA's annual Scientific Sessions meeting
is one of the largest gatherings of health care professionals involved in
diabetes research and the delivery of diabetes care.
